TABLE 3.
Neutralization IC50s for various 4E10 constructs against four HIV-1 clade B isolates
| 4E10 construct | Neutralization IC50 (SE) [relative IC50]a (μM) against HIV isolate: |
|||
|---|---|---|---|---|
| SF162 | SS1196 | HxB2 | JRFL | |
| IgG4E10wt | 0.012 (4) [0.09] | 0.002 (1) [0.03] | 0.005 (1) [0.2] | 0.008 (4) [0.3] |
| IgG4E10[G(L50)E] | 0.009 (6) [0.07] | 0.0015 (7) [0.02] | 0.003 (2) [0.1] | 0.004 (2) [0.1] |
| Fab4E10wt | 0.062 (7) [0.5] | 0.046 (9) [0.7] | 0.007 (4) [0.3] | 0.009* [0.3] |
| Fv4E10wt | 0.13 (2) [1] | 0.07(1) [1] | 0.026(7) [1] | 0.029 (3) [1] |
| Fv4E10[W(H100)A] | >0.8 [>6] | 0.22 (2) [3] | 0.09 (2) [3] | 0.072 (5) [2] |
| Fv4E10[G(L50)E] | 0.1 (2) [0.8] | 0.02 (1) [0.3] | 0.013 (9) [0.5] | 0.0103 (8) [0.4] |
a
Relative IC50s, referenced to Fv4E10wt, are calculated in each column separately for each isolate and are shown in brackets. *, performed only in duplicate, and so no error estimate was calculated.